The CRISPR genome editing technique promises to be a "transformative leap" in genetic engineering and therapy, affecting almost every area of medicine. That includes plastic surgery, with potential advances ranging from prevention of craniofacial malformations, to therapeutic skin grafts, to new types of rejection-free transplants, according to a paper in the November issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
"CRISPR's potential impact on treating human disease includes several areas important to the plastic surgeon such as oncology, wound healing, immunology, and craniofacial malformations," comments ASPS Member Surgeon Eric Chien-Wei Liao, MD, PhD, Director of the Cleft and Craniofacial Program, Laurie and Mason Tenaglia MGH Research Scholar, Massachusetts General Hospital, Harvard Medical School. In a special regenerative medicine article, Dr. Liao and coauthors review the history and mechanisms of CRISPR genome editing, highlighting its potential uses and impact in plastic and reconstructive surgery.
CRISPR Has Implications for Congenital Malformations, Wound Healing, Transplantation and More
CRISPR -- the abbreviation stands for "clustered regularly interspaced short palindromic repeats" -- was discovered as an adaptive immune mechanism in bacteria. Before the development of CRISPR techniques, gene editing was labor intensive and limited to laboratories with advanced molecular biology tools.
"CRISPR gene editing is revolutionizing the potential of gene therapy due to its simplicity, specificity, efficiency, low cost, and versatility," Dr. Liao and coauthors write. "Potential applications of CRISPR are numerous and will certainly impact plastic and reconstructive surgery."
The authors discuss some key areas where CRSIPR has foreseeable implications for plastic surgery, including:
Dr. Liao and colleagues emphasize that many challenges remain in realizing these and other clinical advances with CRISPR gene editing, including potential "off-target" effects, FDA regulation and high costs, and ethical issues related to genetic editing of human cells and tissues. The authors write, "The ASPS and its members should become stakeholders as well, and participate in future debates on the ethical use of CRISPR for the betterment of our patients."
Materials provided by Wolters Kluwer Health. Note: Content may be edited for style and length.
Cite This Page: